Announcements

Take a break and read all about it

Announcements

FDA grants accelerated approval to Tafasitamab-cxix for diffuse large B-cell lymphoma

As of January 2021, the Food and Drug Administration (FDA) has announced the approval of a new medication for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, who are not eligible for autologous stem cell transplant. The new drug, called Monjuvi (tafasitimab) is a targeted therapy that will be used in combination with lenalidomide (Revlimid). Other combinations are currently under investigation.

Announcements

The new GrytHealth.com

Welcome to the new GrytHealth.com! Learn why we chose to update the website and some of the features you’ll be seeing.

Do You Want To Boost Your Business?

drop us a line and keep in touch